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Introduction {#sec005}
============

*Helicobacter pylori*, one of the most common pathogens worldwide, has proven to be associated with gastritis, peptic ulcers, gastric cancer, and mucosa-associated lymphoid tissue (MALT) lymphoma \[[@pone.0147410.ref001]\]. Some individuals when exposed to *H*. *pylori* may escape from persistent infection, even if they live in regions where *H*. *pylori* infection is highly prevalent. Previous studies indicate that host factors may play an important role during *H*. *pylori* infection \[[@pone.0147410.ref002]\]. Host cytokines and their gene polymorphisms may be host factors that affect an individual's susceptibility to *H*. *pylori*-related diseases \[[@pone.0147410.ref003], [@pone.0147410.ref004]\]. *H*. *pylori* infection can induce production of some cytokines, including interleukin (IL)-1, -2, -4, -6, -8, -10, -17, interferon (IFN)-β, and tumor necrosis factor (TNF)-α \[[@pone.0147410.ref005]\]. These host cytokines affect the occurrence and development of the gastric mucosal inflammatory response, which is a key event of *H*. *pylori* infection \[[@pone.0147410.ref006]\].

TNF-α, a host cytokine induced by *H*. *pylori* in gastric mucosal, is supposed to be involved in *H*. *pylori* infection \[[@pone.0147410.ref007]\]. TNF-α is encoded by the *TNFA* gene, which is clustered on the short arm of human chromosome 6 (6p21.3), between *HLA-B* and *HLA-DR* \[[@pone.0147410.ref008]\]. The *TNFA* gene is known to have four single nucleotide polymorphisms in the regulatory sequences that may affect its expression: -308G\>A, -857C\>T, -863 C\>A, and -1031T\>C. TNF-α can inhibit gastric acid secretion and influence the immune response, which may be associated with persistent *H*. *pylori* infection \[[@pone.0147410.ref009]\].

A number of studies have focused on the association between *TNFA* gene polymorphisms and *H*. *pylori*-related diseases \[[@pone.0147410.ref010]--[@pone.0147410.ref012]\]. Previous meta-analysis have demonstrated that *TNFA* gene polymorphisms are associated with gastric cancer and have no association with peptic ulcers \[[@pone.0147410.ref013], [@pone.0147410.ref014]\]. Many studies conducted on gastric diseases have investigated the relationship between *TNFA* gene polymorphisms and *H*. *pylori* infection simultaneously; however, results from these studies are inconclusive. Therefore, we performed this meta-analysis to clarify the association between *TNFA* gene polymorphisms and *H*. *pylori* infection.

Materials and Methods {#sec006}
=====================

Search strategy {#sec007}
---------------

Pubmed, Embase and Cochrane Library databases were searched up to August 2015. The following terms were used for searching: (TNF-α OR tumor necrosis factor-α OR TNF-A OR tumor necrosis factor-A OR TNF-alpha OR tumor necrosis factor-alpha) AND (polymorphism OR polymorphisms OR SNP) AND (*Helicobacter pylori* OR *H*. *pylori* OR HP). Searches were restricted to English. In order to identify potentially relevant studies, the reference lists of retrieved articles were also examined. In addition, the related citations of results in Pubmed were searched. We also contacted the authors to get more data as possible as we can. When more than one of the same case series was involved in several studies, only the study with the largest sample sizes was selected in our meta-analysis.

Selection criteria {#sec008}
------------------

Studies were included if the following conditions were met: (1) A relationship between the *TNFA* gene polymorphisms and *H*. *pylori* infection was described; (2) Case-control designed; (3) Objective *H*. *pylori* infection detection methods were used; (4) Sufficient genotype data to calculate the odd ratios (ORs) with a 95% confidence interval (CI) was available.

Data extraction and quality appraisal {#sec009}
-------------------------------------

The following data were collected from each study: first author's name; year of publication; ethnicity; country; study design; number of cases and controls; *H*. *pylori* infection detection methods; and genotyping method. The Newcastle-Ottawa scale (NOS) \[[@pone.0147410.ref015]\] was used to assess the quality of studies included, according to three main criteria: selection of cases and controls; comparability of cases and controls; and exposure to risk factors. NOS scores ranged between 0 and 9 stars. Studies with a score of seven stars or greater were considered to be of high quality, while those that scored five stars or less were considered low quality. Two authors (XDS and YYX) of this meta-analysis independently extracted all information and conducted the quality appraisal. Disagreements were resolved by discussion with other authors.

Statistical analysis {#sec010}
--------------------

Statistical analysis was performed using STATA 13.1 (STATA Corp, College Station, TX, USA). Pooled OR and corresponding 95% CI was used to measure the strength of associations between *TNFA* gene polymorphisms and *H*. *pylori* infection. Heterogeneity among studies was assessed by the Q-test and I^2^ statistics. *P* \< 0.10 or I^2^ \> 50% indicated significant heterogeneity \[[@pone.0147410.ref016]\]. If significant heterogeneity exists, the ORs were pooled with a random effect model. Otherwise, a fixed effect model was selected. Subgroup analyses were conducted based on *H*. *pylori* infection detection methods (ELISA or non-ELISA methods (including bacterial culture, rapid urease test (RUT), polymerase chain reaction (PCR), urea breath test (UBT), *Helicobacter pylori* stool antigen test (HpSAT) and histological examination)), study designs (hospital-based (HB) or population-based (PB)) and ethnicity (Asian or Caucasian). Publication bias was examined using a Begg's funnel plot or Egger's plot, and the significance level was set at 0.05 for both. Hardy-Weinberg equilibrium was assessed by the χ^2^ test for goodness of fit, with a *P*-value less than 0.05 considered a significant deviation.

Results {#sec011}
=======

Study characteristics {#sec012}
---------------------

A total of 230 articles were retrieved from the initial search. From these, 164 articles were assessed for ineligibility after reading titles and abstracts, and 47 articles with insufficient data were excluded after reading the full texts. In addition, 5 papers were included through references. According to our inclusion and exclusion criteria, 24 articles were used for this meta-analysis finally \[[@pone.0147410.ref017]--[@pone.0147410.ref040]\]. The study selection process is summarized in [Fig 1](#pone.0147410.g001){ref-type="fig"}. Of the studies included, 17 concerned -308 G\>A, nine concerned -857C\>T, four concerned -863C\>A, 10 concerned -1031T\>C; 14 were on Asians, five were on Caucasians, one was on Africans, four were on mixed ethnicity ([Table 1](#pone.0147410.t001){ref-type="table"}).

![Flow diagram of the study selection process.](pone.0147410.g001){#pone.0147410.g001}

10.1371/journal.pone.0147410.t001

###### Main characteristics of studies included in meta-analysis.

![](pone.0147410.t001){#pone.0147410.t001g}

  Author         Year   Country      Ethnicity   Study design   Cases (*Hp*+)   Controls (*Hp-*)   Detection of *Hp*   Genotyping   NOS(score)   HWE(P)                                           
  -------------- ------ ------------ ----------- -------------- --------------- ------------------ ------------------- ------------ ------------ -------- ------------------ ---------------- --- -------
  -308G\>A                                                                                                                                                                                        
  Kunstmann      1999   Germany      Caucasian   HB             10              50                 145                 8            39           132      RUT,HE,BC          ASH              5   0.055
  Li             2005   China        Asian       PB             3               37                 314                 0            24           96       ELISA              RFLP             7   0.102
  Lu             2005   China        Asian       HB             3               59                 351                 1            15           84       HE,BC              SSOP             6   0.989
  Kim            2006   Korea        Asian       PB             9               172                982                 3            23           159      ELISA,RUT,HE,BC    Taqman, RFLP     6   0.153
  Sugimoto       2007   Japan        Asian       HB             0               11                 462                 0            3            169      ELISA,RUT          RFLP             6   1.000
  Chakravorty    2008   India        Asian       HB             3               33                 117                 6            36           115      RUT,HE,BC          RFLP             5   0.174
  Szoke          2008   Hungary      Caucasian   HB             1               15                 59                  5            32           106      HE                 RFLP             4   0.322
  Gao            2009   Germany      Caucasian   PB             9               96                 291                 4            29           98       ELISA              Pyrosequencing   8   0.492
  GonzÂlez       2009   Spain        Caucasian   HB             1               12                 44                  0            4            20       RUT,HE             RFLP             5   1.000
  Queiroz        2009   Brazil       Mixed       PB             6               81                 282                 7            42           121      ELISA,UBT          RFLP             7   0.274
  Cheng          2010   China        Asian       HB             4               61                 300                 6            73           360      RUT,HE,BC          RFLP             6   0.434
  Kang           2012   Korea        Asian       HB             2               37                 245                 1            19           96       RUT,HE,BC          RFLP             7   1.000
  Kimang\'a      2012   Kenya        African     HB             0               97                 54                  2            81           36       RUT,HE,HpSAT,PCR   RFLP             4   0
  Santos         2012   Brazil       Mixed       HB             3               50                 122                 0            4            22       RUT,HE,PCR         RFLP             5   1.000
  Queiroz        2013   Brazil       Mixed       HB             0               15                 32                  0            23           55       RUT,UBT,HE,BC      RFLP             6   0.255
  Kulmambetova   2014   Kazakhstan   Asian       PB             1               26                 115                 7            90           326      HE                 Taqman           6   0.784
  Salagacka      2014   Poland       Caucasian   HB             1               32                 68                  2            30           69       RUT                RFLP             5   0.751
  -857C\>T                                                                                                                                                                                        
  Hamajima       2003   Japan        Asian       HB             28              209                507                 14           164          424      ELISA              CTPP             7   0.691
  Lu             2005   China        Asian       HB             6               100                315                 4            26           70       HE,BC              SSOP             6   0.625
  Atsuta         2006   Brazil       Asian       PB             19              146                287                 17           155          326      ELISA              CTPP             8   0.786
  Tseng          2006   Jamaica      Mixed       PB             0               2                  34                  0            8            142      ELISA              Taqman           8   1.000
  Saijo          2007   Japan        Asian       PB             3               64                 170                 11           47           115      ELISA              Taqman           7   0.498
  Sugimoto       2007   Japan        Asian       HB             33              125                315                 7            40           125      ELISA,RUT          RFLP             6   0.179
  Chakravorty    2008   India        Asian       HB             1               10                 142                 1            16           140      RUT,HE,BC          RFLP             5   0.91
  Abdiev         2010   Uzbeks       Asian       HB             1               44                 79                  2            9            31       ELISA              CTPP             5   0.501
  Salagacka      2014   Poland       Caucasian   HB             2               17                 83                  3            23           75       RUT                RFLP             5   0.691
  -863C\>A                                                                                                                                                                                        
  Lu             2005   China        Asian       HB             12              118                293                 3            23           74       HE,BC              SSOP             6   0.703
  Sugimoto       2007   Japan        Asian       HB             12              153                308                 3            44           125      ELISA,RUT          RFLP             6   0.890
  Chakravorty    2008   India        Asian       HB             11              56                 86                  6            42           109      RUT,HE,BC          RFLP             5   0.600
  Salagacka      2014   Poland       Caucasian   HB             3               28                 71                  1            22           78       RUT                RFLP             5   0.939
  -1031T\>C                                                                                                                                                                                       
  Hamajima       2003   Japan        Asian       HB             13              208                540                 21           177          412      ELISA              CTPP             7   0.714
  Lu             2005   China        Asian       HB             5               107                309                 2            20           78       HE,BC              SSOP             6   0.885
  Ando           2006   Japan        Asian       HB             0               49                 141                 3            22           32       ELISA,UBT,HE       CTPP             5   0.935
  Atsuta         2006   Brazil       Asian       PB             14              120                322                 17           149          326      ELISA              CTPP             8   0.996
  Saijo          2007   Japan        Asian       PB             5               80                 152                 7            51           115      ELISA              Taqman           7   0.656
  Sugimoto       2007   Japan        Asian       HB             12              158                303                 2            46           124      ELISA,RUT          RFLP             6   0.461
  Chakravorty    2008   India        Asian       HB             14              60                 79                  30           55           70       RUT,HE,BC          RFLP             5   0.003
  Abdiev         2010   Uzbeks       Asian       HB             1               41                 82                  3            6            33       ELISA              CTPP             5   0.031
  Zhao           2013   Indonesia    Asian       PB             6               16                 11                  36           105          120      UBT                CTPP             7   0.098
  Salagacka      2014   Poland       Caucasian   HB             1               31                 54                  2            31           59       RUT                RFLP             5   0.537

*Hp*: *H*. *pylori*; +: positive; -: negative; 1/1: variant homozygote; 1/2: heterozygote; 2/2: wild type homozygote; PB: population-based; HB: hospital-based; ELISA: enzyme-linked immunosorbent assay; RUT: rapid urease test; UBT: urease breath test; HpSAT: *Helicobacter pylori* stool antigen test; HE: histological examination; BC: bacterial culture; ASH: allele specific hybridization; RFLP: restriction fragment length polymorphism; CTPP: confronting two-pair primers; SSOP: sequence-specific oligonucleotide probe.

Meta-analysis results {#sec013}
---------------------

The *TNFA* gene -308G\>A polymorphism was associated with decreasing *H*. *pylori* infection in recessive and homozygote models (AA+AG *vs*. GG, OR = 0.93, 95% CI = 0.81--1.05; AA *vs*. AG+GG, OR = 0.64, 95% CI = 0.43--0.97; AA *vs*. GG, OR = 0.64, 95% CI = 0.43--0.97; A allele *vs*. G allele, OR = 0.91, 95% CI = 0.81--1.02) ([Fig 2](#pone.0147410.g002){ref-type="fig"}). For the -1031T\>C polymorphism, a significantly decreased risk was also found in recessive model (CC+CT *vs*. TT, OR = 1.00, 95% CI = 0.81--1.23; CC *vs*. CT+TT, OR = 0.61, 95% CI = 0.44--0.84; CC *vs*. TT, OR = 0.63, 95% CI = 0.39--1.03; C allele *vs*. T allele, OR = 0.94, 95% CI = 0.78--1.13). In contrast, the -863C\>A polymorphism was associated with an increasing risk of *H*. *pylori* infection in dominant and allelic models (AA+AC *vs*. CC, OR = 1.47, 95% CI = 1.16--1.86; AA *vs*. AC+CC, OR = 1.58, 95% CI = 0.82--3.03; AA *vs*. CC, OR = 1.77, 95% CI = 0.92--3.43; A allele *vs*. C allele, OR = 1.40, 95% CI = 1.14--1.72). There was no significant association between the -857C\>T polymorphism and *H*. *pylori* infection ([Table 2](#pone.0147410.t002){ref-type="table"}).

![Forest plots for all models to show an association between the *TNFA* -308G\>A polymorphism and *H*. *pylori* infection.](pone.0147410.g002){#pone.0147410.g002}

10.1371/journal.pone.0147410.t002

###### Meta-analysis of the association between *TNFA* polymorphisms and *H*. *pylori* infection.

![](pone.0147410.t002){#pone.0147410.t002g}

  Study Group   Study(n)   Dominant model   Recessive model   Homozygote model   Allelic model                                                                                            
  ------------- ---------- ---------------- ----------------- ------------------ --------------- ---------------- ------- ---------- ---------------- ------- ---------- ---------------- -------
  -308G\>A                                                                                                                                                                                
  Total         17         0.93             0.81--1.05        0%                 **0.64**        **0.43--0.97**   0%      **0.64**   **0.43--0.97**   0%      0.91       0.81--1.02       0%
  ELISA         5          0.88             0.71--1.10        38.8%              0.57            0.30--1.11       0%      0.57       0.29--1.09       0%      0.86       0.70--1.05       19.9%
  Non-ELISA     12         0.95             0.81--1.11        0%                 0.69            0.41--1.15       0%      0.69       0.41--1.15       0%      0.94       0.81--1.08       0%
  Asian         8          0.88             0.73--1.05        0%                 0.65            0.34--1.22       0%      0.63       0.34--1.19       0%      0.87       0.74--1.03       0%
  Caucasian     5          1.06             0.82--1.36        0%                 0.82            0.43--1.56       0%      0.84       0.44--1.60       0%      1.02       0.82--1.28       0%
  HB            12         0.98             0.82--1.16        0%                 0.72            0.42--1.22       0%      0.72       0.42--1.23       0%      0.96       0.83--1.11       0%
  PB            5          0.85             0.70--1.05        35.4%              0.55            0.30--1.03       0%      0.54       0.29--1.02       0%      0.84       0.70--1.01       13.2%
  -857C\>T                                                                                                                                                                                
  Total         9          1.04             0.91--1.19        16%                0.81            0.44--1.49       55.5%   0.81       0.43--1.52       56.7%   0.98       0.82--1.17       42.5%
  ELISA         6          1.10             0.95--1.28        0%                 0.91            0.43--1.93       67.3%   0.94       0.45--2.00       67.3%   1.09       0.96--1.24       36.2%
  Non-ELISA     3          0.72             0.51--1.02        0%                 0.50            0.18--1.36       0%      0.47       0.17--1.29       0%      **0.72**   **0.52--0.98**   0%
  Asian         7          1.06             0.92--1.21        22.3%              0.81            0.41--1.58       61.1%   0.82       0.42--1.62       61.9%   1.00       0.83--1.21       50.3%
  HB            6          1.06             0.90--1.26        34.4%              1.25            0.81--1.92       40.4%   1.27       0.82--1.97       41.6%   1.07       0.93--1.24       44.4%
  PB            3          0.99             0.79--1.24        0%                 0.53            0.08--3.34       84.6%   0.53       0.08--3.49       85.2%   0.91       0.63--1.31       52.5%
  -863C\>A                                                                                                                                                                                
  Total (HB)    4          **1.47**         **1.16--1.86**    0%                 1.58            0.82--3.03       0%      1.77       0.92--3.43       0%      **1.40**   **1.14--1.72**   0%
  Non-ELISA     3          **1.50**         **1.11--2.02**    0%                 1.62            0.76--3.46       0%      1.83       0.85--3.94       0%      **1.43**   **1.11--1.86**   0%
  Asian         3          **1.47**         **1.14--1.90**    0%                 1.48            0.75--2.93       0%      1.67       0.84--3.32       0%      **1.39**   **1.11--1.74**   0%
  -1031T\>C                                                                                                                                                                               
  Total         10         1.00             0.81--1.23        55.4%              **0.61**        **0.44--0.84**   34.7%   0.63       0.39--1.03       40.3%   0.94       0.78--1.13       59.7%
  ELISA         6          0.96             0.72--1.27        67.9%              0.57            0.28--1.13       48.6%   0.57       0.28--1.15       49.3%   0.91       0.72--1.16       67.2%
  Non-ELISA     4          1.06             0.81--1.39        23.8%              0.60            0.36--1.01       26.0%   0.63       0.37--1.08       42.1%   1.01       0.71--1.42       56.7%
  Asian         9          1.00             0.79--1.25        60.1%              **0.62**        **0.38--1.00**   41.9%   0.63       0.38--1.06       46.9%   0.94       0.77--1.15       63.9%
  HB            7          0.99             0.74--1.32        63.1%              **0.48**        **0.32--0.72**   29.1%   **0.48**   **0.32--0.73**   33.7%   0.91       0.70--1.18       67.7%
  PB            3          0.95             0.76--1.18        49.1%              0.90            0.53--1.51       0%      0.91       0.54--1.56       18.2%   0.95       0.79--1.14       41.6%

Significant results were shown in bold.

Variable *H*. *pylori* infection detection methods were used in the studies included in this meta-analysis ([Table 1](#pone.0147410.t001){ref-type="table"}). These methods were different in sensitivity and specificity, and various methods could cause various results of diagnosing *H*. *pylori* infection. ELISA method had special features during *H*. *pylori* epidemiological survey, so we performed a subgroup analysis for ELISA and non-ELISA methods. The *TNFA* -308G\>A and -1031T\>C polymorphisms had no association with *H*. *pylori* infection for ELISA or non-ELISA subgroups. -857C\>T polymorphism significantly decreased the risk of *H*. *pylori* infection in allelic model for the non-ELISA subgroup, and -863C\>A polymorphism increased the risk in dominant and allelic models for the non-ELISA subgroup. We also conducted a subgroup analysis on ethnicity. The results showed that the -863C\>A polymorphism had a significant association with *H*. *pylori* infection in dominant and allelic models for the Asian subgroup, and -1031T\>C polymorphism was associated with *H*. *pylori* infection in recessive model for the Asian subgroup too. -308G\>A and -857C\>T polymorphisms did not have significant association with *H*. *pylori* infection for Asian or Caucasian subgroups. A stratified analysis on study design was also performed, and the results indicated that -863C\>A significantly increased the risk and -1031T\>C decreased the risk for HB subgroups. All results of the meta-analysis are shown in [Table 2](#pone.0147410.t002){ref-type="table"}.

Heterogeneity and sensitivity analysis {#sec014}
--------------------------------------

Significant heterogeneity was observed in the *TNFA* -857C\>T and -1031T\>C polymorphism results. We then conducted sensitivity analysis to identify the results by omitting one study in turn. Heterogeneity decreased when a study by Saijo *et al*. \[[@pone.0147410.ref034]\] was excluded for the -857C\>T polymorphism and a study by Ando *et al*. \[[@pone.0147410.ref021]\] was excluded for the -1031T\>C polymorphism. The pooled ORs were not significantly altered in all investigated SNPs by sequential omission of included studies.

Publication bias {#sec015}
----------------

Begg's funnel plot of SNPs did not reveal any evidence of significant publication bias ([Fig 3](#pone.0147410.g003){ref-type="fig"}). Begg's or Egger's tests also showed no statistical significance for examining publication bias in the dominant model (-308G\>A, Begg's test *P* = 0.27, Egger's test *P* = 0.26; -857C\>T, Begg's test *P* = 0.60, Egger's test *P* = 0.35; -863C\>A, Begg's test *P* = 1.00, Egger's test *P* = 0.98; and -1031T\>C, Begg's test *P* = 0.37, Egger's test *P* = 0.28).

![Begg's funnel plot of all studies included in the meta-analysis for -857C\>T polymorphism.\
Se: standard error.](pone.0147410.g003){#pone.0147410.g003}

Discussion {#sec016}
==========

Results of our meta-analysis indicate that *TNFA* -308G\>A and -1031T\>C polymorphisms might be associated with a decreasing risk of *H*. *pylori* infection, while the -863C\>A polymorphism could increase the risk of *H*. *pylori* infection. When stratified analysis was conducted on ethnicity in our meta-analysis, only -863C\>A and -1031T\>C polymorphisms had significant association with *H*. *pylori* infection in Asian population. -308G\>A and -857C\>T polymorphisms had no significant association with *H*. *pylori* infection in Asian or Caucasian population. *TNFA* polymorphisms did not show up in a genome wide association study in Europeans \[[@pone.0147410.ref041]\], which was consistent with the results of our meta-analysis in Caucasian subgroup. The association between *TNFA* polymorphisms and *H*. *pylori* infection may be more meaningful in Asian population. When stratified for study design, -863C\>A significantly increased the risk and -1031T\>C decreased the risk for the HB subgroups.

Significant heterogeneity existed in meta-analysis results of -857C\>T and -1031T\>C polymorphisms, and heterogeneity decreased after excluding the study of Saijo *et al*. \[[@pone.0147410.ref034]\] for -857C\>T polymorphism and the study of Ando *et al*. \[[@pone.0147410.ref021]\] for -1031T\>C polymorphism, which suggests that the above two studies might be the source of heterogeneity. Subjects of the study by Saijo *et al*. were all healthy Japanese transit company employees whose ages ranged from 35--60 years, including 413 men and only 5 women. Specific gender, age and occupational composition of the subjects might lead to the difference between the study by Saijo *et al*. and other including studies. 41% of the subjects of the study by Ando *et al*. suffered from gastro-oesophageal reflux disease, which might be the source of heterogeneity between the study by Ando *et al*. and other including studies. No significant difference with pooled ORs was shown in the sensitivity analysis. In our study selection process, two studies on -238G\>A, one study on -555G\>A, and one study on -806C\>T investigated the association with *H*. *pylori* infection, and all reported no significant association. We did not conduct a meta-analysis in three *TNFA* SNPs \[[@pone.0147410.ref020], [@pone.0147410.ref027], [@pone.0147410.ref040]\].

Numerous methods have been developed for diagnosing *H*. *pylori* infection, such as bacterial culture, RUT, PCR, UBT, histological examination and serum antibody detection \[[@pone.0147410.ref042]\]. Bacterial culture, RUT, UBT and histological examination can be affected by biopsy location, bacterial density and morphology, fastidious growth requirements, and so on \[[@pone.0147410.ref043]\]. Serology could not distinguish between current and past *H*. *pylori* infection, but an IgG-positive sample can show that the host is susceptible to *H*. *pylori* \[[@pone.0147410.ref044]\]. Since variable *H*. *pylori* infection detection methods were used in studies included in our meta-analysis, which could cause different results of diagnosing *H*. *pylori* infection, we conducted subgroup analyses (ELISA *vs*. non-ELISA methods) to verify the association between *TNFA* polymorphisms and *H*. *pylori* infection. A significant association was found between the *TNFA* -863C\>A polymorphism and *H*. *pylori* infection for the non-ELISA subgroup in dominant and allelic models, and between -857C\>T and *H*. *pylori* infection for the non-ELISA subgroup in allelic model. -308G\>A and -1031T\>C polymorphisms had no association with *H*. *pylori* infection for ELISA or no-ELISA subgroups.

Gastric acid secretion is supposed to be inhibited by TNF-α, which was produced by macrophages in the gastric submucosa \[[@pone.0147410.ref045]\]. Since the *TNFA* -863A polymorphism is related to high transcriptional promoter activity \[[@pone.0147410.ref046]\], carriers of the *TNFA* -863A polymorphism may have a significantly higher level of TNF-α than those with the C allele. High concentrations of TNF-α could directly suppress gastric acid secreted by parietal cells, and simultaneously inhibit the functions of gastrin-stimulated enterochromaffin-like cells to decrease the secretion of histamine, which can elevate gastric secretion \[[@pone.0147410.ref046]\]. In addition, a high level of TNF-α could amplify inflammatory responses by activating neutrophils, T cells, and B cells. Low levels of gastric acid, and an aggressive inflammatory response, can facilitate the colonization of the gastric mucosa with *H*. *pylori* from the gastric antrum to the corpus \[[@pone.0147410.ref009]\]. This might increase the risk of developing atrophic gastritis, or even gastric cancer.

Although there are papers reporting that -308G\>A and -1031T\>C polymorphisms are also related to high transcriptional promoter activity \[[@pone.0147410.ref047]--[@pone.0147410.ref049]\], our meta-analysis revealed that -308G\>A and -1031T\>C polymorphisms could decrease the risk of *H*. *pylori* infection. This difference may be linked with the sample size and ethnicity. Moreover, TNF-α possibly regulates *H*. *pylori* infection through other mechanisms. Further studies are needed to confirm the mechanisms.

There were some limitations to this study. Firstly, most of the studies included for -857C\>T, -863C\>A, and -1031T\>C polymorphisms were conducted on Asian populations, so further research with other ethnic populations are needed. Secondly, only a low number of studies were included. Therefore, more studies involving much larger sampling sizes should be conducted. Thirdly, it is also possible that language bias might exist, as our meta-analysis only included articles published in English.

Conclusions {#sec017}
===========

This meta-analysis is the first to investigate the association between *TNFA* polymorphisms and *H*. *pylori* infection. Our conclusion suggests that *TNFA* -308G\>A and -1031T\>C polymorphisms may be associated with a decreasing risk of *H*. *pylori* infection, and the -863C\>A polymorphism may be associated with an increased risk of *H*. *pylori* infection. There was no significant association between -308G\>A and *H*. *pylori* infection for Asian or Caucasian subgroups. *TNFA* -863C\>A and -1031T\>C polymorphisms had significant associations with *H*. *pylori* infection for Asian and HB subgroups, and -857C\>T and -863C\>A polymorphisms had significant associations with *H*. *pylori* infection for non-ELISA subgroup. Further studies with different ethnicities and larger sample size are required to validate our results.
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